Andrew Stelzer

Digital

Web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about effectively implementing AI.

News

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.